Donor leukocyte infusion (DLI) has well-documented activity in CML but the role of DLI in other diseases is less well defined. To evaluate the strategy in acute lymphocytic leukemia (ALL) we evaluated 44 ALL patients from 27 centers who were treated with DLI. Patients with persistent or recurrent disease received DLI from the original marrow donor (30 matched related, four mismatched family, and 10 matched unrelated). Chemotherapy was given before DLI to 28 patients. Of 15 patients who received no pre-DLI chemotherapy, two achieved complete remissions, lasting 1112 and 764+ days. In four patients who received DLI as consolidation of remission induced by chemotherapy or immunosuppression-withdrawal, duration of remission post DLI was 65, 99, 195 and 672+ days. Of 25 patients who received DLI in the nadir after chemotherapy, 13 survived у30 days post DLI but did not achieve remission, seven died within less than 30 days post DLI, and five entered remissions that lasted 42, 68, 83, 90, 193 days. Seven patients who did not respond to the initial DLI received a second DLI; none of these patients attained durable remission. Eighteen of 37 evaluable patients developed acute GVHD and five of 20 evaluable patients developed chronic GVHD. Overall actuarial survival is 13% at 3 years. In conclusion, DLI has limited benefit in ALL. New approaches are needed in this group of patients. Bone Marrow Transplantation (2000) 26, 511-516. Keywords: acute lymphocytic leukemia; donor leukocyte infusions; adoptive immunotherapy Data from animal experiments and from clinical observations strongly support the existence of a graft-versus-leukemia (GVL) effect of allogeneic bone marrow transplantation (BMT).
Data from animal experiments and from clinical observations strongly support the existence of a graft-versus-leukemia (GVL) effect of allogeneic bone marrow transplantation (BMT). [1] [2] [3] [4] [5] Based on the power of this effect and its mediation by donor immune cells, several groups have treated patients in relapse after allogeneic BMT with donor leukocyte infusions (DLI) [6] [7] [8] [9] [10] [11] [12] [13] row donor. Leukocytes are collected from the donor by leukapheresis or phlebotomy and infused, generally without concurrent immunosuppression. DLI is most effective for chronic myelogenous leukemia (CML). 11, 13 Complete responses to DLI are seen in about 70% of patients with CML in early relapse (cytogenetic and chronic phase). Graft-versus-host disease (GVHD) occurs in approximately 60% of patients and correlates closely with disease response. 13 The role of DLI in acute lymphocytic leukemia (ALL) is less certain. Durable remission after DLI for ALL has been reported; [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] in fact, the first successful DLI was in a patient with ALL. 12, 14 However, the number of ALL cases reported is relatively small and the few successful cases reported may represent positive reporting bias. To investigate further the role of DLI in ALL, we collected retrospective and prospective data on 44 patients reported from 27 BMT centers.
Patients and methods

Design
We collected detailed information from 27 BMT centers about DLIs in 44 patients with ALL. The data on 27 of these patients were collected retrospectively; 17 patients were part of a prospective trial. In the prospective trial, patients with ALL in hematologic relapse were treated first with reinduction chemotherapy. Standard vincristine, prednisone, and daunorubicin were recommended, but variation was allowed based on clinical judgment. In the nadir after chemotherapy (approximately days 10-14 after chemotherapy initiation), patients received DLIs from their original bone marrow donor. For HLA-identical sibling DLI, donor leukocytes were collected by apheresis after G-CSF mobilization (G-CSF 10 g/kg daily for 4-6 days with apheresis on day 4 and subsequent days if necessary). The target CD3-positive cell yield was 1 × 10 8 cells/kg and the target CD34-positive cell yield was 2 × 10 6 cells/kg, with the CD3-positive cell dose taking precedence over the CD34-positive cell dose. For mismatched related family member DLI, and for matched unrelated DLI, unmobilized leukocytes were collected by phlebotomy or apheresis with a target cell dose of 1 × 10 6 CD3-positive cells/kg in mismatched related family members and 1 × 10 7 CD3-positive cells/kg in matched unrelated donors. Cells were given intravenously the same day of collection or the day after.
Patients did not receive post-DLI immunosuppression. Information collected both retrospectively and prospectively included the following: demographics -patient sex, age, and race; diagnosis -disease, date of diagnosis, cytogenetic abnormalities, treatment before BMT, and response to treatment; BMT -pre-BMT performance status, pre-BMT disease status, donor relationship, sex, and degree of histocompatibility, whether the BMT was T cell-depleted, conditioning regimen and GVHD prophylaxis, occurrence of acute and chronic GVHD, and donor chimerism post BMT; post-BMT relapse -date and extent of relapse, donor chimerism at relapse, and treatment of relapse and response to treatment; DLI -pre-DLI performance status, disease status, pre-DLI chemotherapy and response, date of DLI, total nucleated cell dose, mononuclear cell dose, T cell dose, and concomitant cytokine usage; post-DLI response and complications -response to DLI and date, percent of donor chimerism before and after DLI (assessed by either DNA polymorphism analysis or standard cytogenetic analysis), occurrence of pancytopenia and date, treatment of pancytopenia and response, occurrence and grade of acute GVHD, occurrence and extent of chronic GVHD, prophylaxis and treatment of GVHD, response of GVHD to treatment, infectious complications, post-DLI relapse date, and extent of relapse; and last contact -performance status, GVHD status, disease status, and date and cause of death.
For the purposes of this analysis, retrospective and prospective data were pooled. Fifteen patients had been reported previously. 13 
Definitions
Relapse was defined as cytogenetic in patients in whom the only evidence of relapse was reappearance of a diseasespecific chromosome abnormality; all other relapses were defined as hematologic. Complete response was defined as resolution of abnormal blood and bone marrow morphology, with fewer than 5% blasts and resolution of disease-specific chromosome abnormalities (if present) by standard cytogenetic analysis. Acute and chronic GVHD were graded by standard clinical criteria. 27, 28 Pancytopenia was defined as an absolute neutrophil count of less than 500/l and/or platelet count less than 20 000/l, not deemed to be due to disease or chemotherapy.
Eligibility criteria for the analysis
Patients were considered not evaluable for disease response if they received DLI after having been induced into remission by chemotherapy or had complete responses after having received DLI in the nadir post chemotherapy. Patients were considered evaluable for acute GVHD and chronic GVHD if they survived 30 and 100 days post DLI, respectively.
Statistical analysis
Survival curves were estimated using the method of Kaplan-Meier. 29 Patients were censored at their time of last contact. Confidence intervals for survival were calculated using the log-transformation method.
30
Results
Patient demographics
Demographics of 44 ALL patients receiving DLI are shown in Table 1 .
Pre-DLI therapy
Twenty-eight patients received chemotherapy before DLI ( received interferon alpha before DLI. After DLI, three patients received GM-CSF, one patient received IL-2, one patient received interferon alpha and one patient received interferon gamma. The median follow-up duration after DLI was 83 days (range 2-1210) and in survivors, the median follow-up duration was 364 days (range 20-1210). Eight patients received a second DLI (discussed below).
Disease response
Regarding the first DLI (Table 3) , of 15 patients who received no pre-DLI chemotherapy, two achieved complete remissions, lasting 1112 and 764+ days. Among four patients who received DLI as consolidation of remission, duration of remission post-DLI was 65, 99, 195 and 672+ days. Of 25 patients who received DLI in the nadir after chemotherapy, 13 survived у30 days but did not achieve remission, seven died less than 30 days post DLI (of infection, GVHD or progressive disease), and five entered remissions that lasted 42, 68, 83, 90 and 193 days (four relapses, one death due to GVHD). Seven of the 13 patients (Table 3) . One patient received a second DLI without prior chemotherapy after relapsing from a remission which had been induced by chemotherapy and consolidated by DLI. The patient again achieved a complete remission that is ongoing at 137+ days. The other seven patients received second DLI after having no response to the first DLI. One of these received DLI to consolidate chemotherapy-induced remission; however, the remission lasted only 23 days. Another patient received DLI in the nadir after chemotherapy; remission was obtained but lasted only 67 days. The five remaining patients did not have chemotherapy prior to second DLI; two of these patients had transient complete responses which lasted 19 and 33 days.
In summary, regardless of pre-DLI chemotherapy or number of DLIs, only three of 44 patients obtained remissions of a year or more; one additional patient is still in remission at 137+ days.
Complications
Eighteen of 37 evaluable patients developed acute GVHD (one grade I, four grade II, eight grade III, five grade IV), and five of 20 evaluable patients developed chronic GVHD (two limited and three extensive). The median time to development of acute GVHD was 28 days. No patients developed pancytopenia believed to be related to DLI. Death following DLI was attributed to progressive disease (26) , GVHD (four), infection (two), respiratory failure (two) cerebral infarct (one) and aspiration pneumonia (one) ( Table 4) .
Overall survival
Overall actuarial survival for the 44 patients is 13% at 3 years ( Figure 1 ). a Cerebral infarction (one), aspiration pneumonia (one), respiratory failure (two). 
Discussion
Our analysis of 44 patients shows that DLI has limited benefit in patients with ALL in relapse after allogeneic BMT. Approximately 75% of patients treated with DLI, either alone or in the nadir after chemotherapy did not achieve complete remission. Of the 11 patients who were in complete remission after the first DLI, eight either relapsed within a few weeks to months or died of toxicity. Only three patients achieved remission of a year or more. Several patients who received DLI for ALL have been reported previously. Slavin et al 12 reported a 30-month-old boy with persistent ALL 1 month after T cell-depleted BMT. The patient received vincristine, prednisone, lowdose methotrexate and local irradiation followed by graded increments of donor leukocytes. The patient had a complete remission associated with grade II acute GVHD and remains in remission several years later. Slavin et al 12 reported five additional patients with ALL treated with DLI. Two patients received DLI for minimal residual disease and were alive and well 24 and 37 months after the procedure. Of three additional patients treated for progressive disease, one who was treated with allogeneic lymphocytes activated in vitro with IL-2 and given along with in vivo IL-2 had a complete remission and was alive and well at Ͼ5 years post DLI. Numerous additional case reports have documented complete remissions, usually associated with GVHD, in ALL patients receiving DLI. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Thus, the potential for anti-leukemic activity of this therapy in ALL is clear. However, the overall utility of the approach is less certain, since reporting bias on single case reports is likely to exaggerate the benefits of the therapy. Thus, larger series of patients reported by multiple centers to registries of DLI may provide a more accurate evaluation of the approach. Although there are drawbacks of analyses derived from such registries such as heterogeneity of treatment regimen and intercenter differences in assessing and grading some outcomes, the endpoint of survival is straightforward. Our report shows that the likelihood of survival after DLI for ALL is low, less than 15% at 3 years. Fortytwo ALL patients from a European registry were briefly summarized recently; the likelihood of survival was approximately 10% at 3 years and 0% at 4.5 years. 31 The reason for the low efficacy of DLI in ALL patients is uncertain. A large retrospective analysis has suggested that the GVL effect in ALL is particularly associated with GVHD and is not as pronounced as in CML and AML. 5 The majority of the patients in our study did not have significant GVHD after initial BMT, suggesting that histocompatibility differences were not pronounced enough in these patients to lead to GVHD and associated GVL. However, only two of 18 evaluable patients developing acute GVHD after DLI achieved durable complete remission. Of interest, of the three patients who developed durable CR, two had chronic GVHD.
Poor activity of DLI for ALL may also be explained by defective antigen presentation by the ALL cells or inadequate expression by ALL cells of critical surface molecules such as adhesion molecules, co-stimulatory molecules, and class I and II HLA molecules. [32] [33] [34] [35] [36] For example, one study suggested that pre-B ALL cells may be incapable of inducing T cell responses due to their inability to function as APC and to their potential to induce tolerance. 36 The clinical relevance of these issues has yet to be established. It is also likely that the leukemia burden is too high in patients with hematologic relapse; patients might die from rapid disease progression before GVL effects have a chance to evolve. An approach to this issue might involve the administration of chemotherapy before DLI; however, only one of 28 patients treated by this approach had durable disease-free survival in our study. Another approach to this problem might be careful monitoring of minimal residual disease and DLI at the earliest appearance of disease recurrence; this approach is untested in this series. Finally, it is possible that donor leukocytes alone may be inadequate; additional lymphocyte activation or expansion, such as by IL-2 12 or the transfer of in vitro expanded leukemia-specific T cells, 37 might be required. In conclusion, durable and significant responses to DLI in ALL patients are uncommon. Relapsed ALL patients should be considered candidates for alternative approaches, including palliation. Additional research is warranted into mechanisms of resistance and development of new therapies.
